Chronic kidney disease (CKD) is a disease of industrialized societies, and it affects approximately 11% of the population in developed countries. Some small-scale studies support that the acid-producing diets typical of industrialized societies contribute to CKD progression. In the USA alone, 11.2 million people are estimated to have Stage 1 and 2 CKD, and continuation of their acid-producing diets without alkali intervention might increase their risk for progression. The social and economic costs of CKD are high, and its prevalence and high treatment costs indicate a need for effective, safe, easily available, and inexpensive prevention. Currently recommended kidney-protective strategies fail to stop CKD in all patients, suggesting a need for complimentary or adjunctive therapies. Important acid-base-related factors that might contribute to the pathology and prevention of CKD include the following: 1. Individuals with CKD have a reduced number of functioning nephrons, obligating more acid excretion per remaining nephron in response to the acid-producing diet typical of industrialized societies. 2. Kidney mechanisms used to augment nephron acid excretion accomplish the short-term physiological goal of increased acid excretion, but these mechanisms might have pathological long-term consequences, including mediating progressive nephropathy. 3. One approach to CKD prevention or progression includes reducing the dietary acid load that must be excreted by the kidney through ingestion of a less-acid-producing diet or adding a base, such as NaHCO 3 . 4. Consequently, in addition to being effective, CKD prevention must be widely available, well tolerated, and inexpensive.
NAHCO 3 IN NEPHROLOGY
Sodium bicarbonate (NaHCO 3 ) is used in the treatment of a wide variety of metabolic acidoses, including renal tubular acidosis, and such treatment has been the topic of many textbooks of nephrology and reviews. It is also used to alkalize urine in patients with cystitis to provide symptomatic relief and prevent the formation of uric acid stones in the kidney. More recently, consideration for the therapeutic use of NaHCO 3 has broadened to include its wider use in CKD management and/or prevention.
PATHOPHYSIOLOGICAL BACKGROUND
The typical diet of individuals living in industrialized societies is high in acid-producing animal protein and comparatively low in base-producing proteins derived from fruits and vegetables (F þ V). This diet produces about 1 mEq of hydrogen ions (protons)/kilogram body weight (b.w.)/ day. 1 Elimination of protons and regeneration of alkali is done primarily by the kidney, but a detailed description of these processes is beyond the scope of this review. The proposed mechanisms by which acidosis in CKD can worsen the progression of the disease and that are responsible for complications are shown in Figure 1 . 1 Metabolic acidosis due to CKD has been associated with progressive deterioration of kidney function in experimental animals 2 and patients. 3 On the other hand, a U-shaped association was found between serum bicarbonate concentration ([HCO 3 ]) and all-cause mortality in CKD patients. 4 Depending on the study, the optimal serum [HCO 3 ] in CKD varies widely, ranging from 22 to 32 mEq/l. 5 Kanda et al. 6 found that low (o25th percentile) serum bicarbonate level is associated with CKD progression, and a 1-mEq/l increase in serum bicarbonate level (in normal range) was associated with low risk of CKD progression Dobre et al. 7 showed that low serum bicarbonate was an independent risk factor for CKD progression. On the other hand, the risk of heart failure in CKD patients was increased by 14% per 1-mEq/l increase in serum bicarbonate level over 24 mEq/l, i.e., in normal range. 7 Other studies showed a direct and positive association between net endogenous acid production and progression of kidney disease. 8 Because humans with reduced glomerular filtration rate (GFR), 9 similar to experimental animals with reduced GFR, 10 might have acid retention without reduced serum HCO 3 , reduced GFR without metabolic acidosis might also increase the risk for kidney disease. These observations led to interventional studies to help establish an alkalization strategy in CKD patients.
EXPERIMENTAL STUDIES
Laboratory studies of CKD have typically used the 5/6 nephrectomy (Nx) model with metabolic acidosis 2,10 and the 2/3 Nx model that has greater GFR preservation but has acid retention (determined by kidney and skeletal muscle microdialysis) and no metabolic acidosis. 11 The favorable effect of NaHCO 3 and other alkali supplementation in different CKD animal models is shown in Table 1 .
CLINICAL STUDIES
Small-scale studies that show a beneficial effect of oral NaHCO 3 supplementation in CKD patients are presented in Table 2 . Nevertheless, nephrologists appropriately await results of larger, long-term clinical studies before altering currently recommended CKD treatment strategies.
MECHANISMS OF ACTION
NaHCO 3 given orally supplies bicarbonate ions indirectly (exchange of one HCO 3 À ion for each H þ ion used in the reaction in the gastric lumen; Figure 2 ) and directly (absorption from gastrointestinal tract, especially important in case of enteric capsules). There are several hypotheses explaining the apparent benefit of NaHCO 3 in CKD patients. The acid environment of metabolic acidosis and/or acid retention might itself induce kidney injury, and alkalinization might reduce this injury directly by ameliorating this acid environment. On the other hand, dietary acid intake might cause kidney injury indirectly. Dietary acid augments kidney acidification through increased production of endothelin, aldosterone, and angiotensin II. 11 These agents augment distal nephron acidification in the short term, but might increase kidney inflammation and fibrosis over the longer term if increased dietary acid intake is sustained. 2 Therefore, alkalization that reduces acid retention 9 might be equivalent to drug therapies that reduce kidney levels of and/or effects of angiotensin II, endothelin, and aldosterone 11 and might thereby provide kidney protection with a better safety profile than pharmacological antagonists of angiotensin II, endothelin, and aldosterone. Some animal 10, 11 and human 14 studies suggest that dietary acid augments progressive nephropathy in the setting of reduced GFR in the absence of metabolic acidosis. Animals 10 and humans 9 with reduced GFR appear to have acid retention that is not reflected by plasma acid-base parameters Figure 1 | To maintain isohydria, nephrons show an increase in the production of ammonia, which induces nonenzymatic activation of alternative complement pathway and synthesis of inflammatory mediators. Another nephrotoxic agent is endothelin-1 (ET-1), which induces vasoconstriction, inflammation, and fibrosis, as well as renal acidification. This activity is associated with angiotensin II and free-radical reactions. Increased ET-1 synthesis is caused by acid retention concomitant with decreased glomerular filtration rate, which also causes increased serum aldosterone concentration. Further consequences of acidosis include disturbances of muscle and bone metabolism, leading to renal osteodystrophy. CKD, chronic kidney disease; RAS, renin-angiotensin system. m i n i r e v i e w I Łoniewski and DE Wesson: Bicarbonate therapy and CKD but is ameliorated by dietary alkali. This proposed acid retention associated with reduced GFR without metabolic acidosis increases kidney levels of endothelin, aldosterone, and angiotensin II in animals 11 and plasma endothelin and aldosterone levels in humans. 14 The signal(s) leading to these changes in the absence of frank metabolic acidosis are not known but might include pH 'sensors' 19 located in extra plasma compartments such as the kidney interstitium. 10 Consequently, dietary NaHCO 3 might be protective in patients with reduced GFR without metabolic acidosis through the reduction of associated acid retention. The potential kidney-protective effects in patients with reduced GFR but no metabolic acidosis raises consideration as to whether it should be recommended kidney protection earlier in the course of CKD progression. Additional studies are necessary to establish precise criteria for indications concerning such therapy in CKD patients.
SAFETY Side effects
In clinical studies to date, NaHCO 3 has had few notable side effects when given to CKD patients. 13, 16, 18 Most of the common side effects were caused by CO 2 released through a reaction in the stomach, as shown in Figure 2 , and included belching, gastric distension, and flatulence. Practitioners must be aware that higher alkali doses might cause fluid retention and worse blood pressure control in patients treated with very low GFR.
Short-term 15 and long-term 14 studies also show that NaHCO 3 therapy can reduce serum potassium, an outcome that can be beneficial in CKD patients who are at increased risk of hyperkalemia, particularly in the later stages of CKD and in such patients taking angiotensin-converting enzyme inhibitors. 18 
COMPLICATIONS Metabolic alkalosis with exogenous HCO 3
Exogenous NaHCO 3 rarely causes metabolic alkalosis in patients with normal GFR and normal extracellular fluid volume, 20 and it did not increase serum [HCO 3 ] above normal when given for 1 year at 1 mEq/kg b.w./day (5.9 g /day for 70 kg b.w.) to CKD stage 4 patients with metabolic acidosis. 17 Therefore, NaHCO 3 at doses mostly used in CKD patients (2-3 g/day) is unlikely to cause this complication. However, practitioners and patients must be mindful of all circumstances that can cause metabolic alkalosis (e.g., vomiting, diarrhea, and hypokalemia), and in such cases NaHCO 3 should be temporarily discontinued. The recent study by Dobre et al. 7 revealed that even a slight increase of serum bicarbonate over 24 mmol/l is associated with increased heart failure risk. Results of this study should increase vigilance when long-term alkali treatment is being considered.
A special situation that can cause metabolic alkalosis is simultaneous ingestion of NaHCO 3 and non-absorbable antacids (aluminum and magnesium carbonate) in combination with cation-exchange resins. 20 This situation causes the formation of water-soluble and easily absorbable NaHCO 3 in the small intestine. 20 In this case, metabolic alkalosis can occur when base excretion from the extracellular fluid is limited.
Another possible complication of NaHCO 3 therapy is milk alkali syndrome that occurs only when NaHCO 3 is administered with calcium. This syndrome occurs in patients who ingest large quantities of milk and antacids (to treat peptic ulcer disease), or, recently, in patients using calcium alkali salts to treat osteoporosis or individuals habitually chewing betel nuts in Asia. 21 Therefore, caution is required during simultaneous use of NaHCO 3 and calcium carbonate. Calcium carbonate has a lower alkalizing potential than NaHCO 3 , 22 and it can cause milk alkali syndrome and vessel calcification. Therefore, calcium carbonate should not be used as the primary alkalinization agent for CKD patients.
Spontaneous rupture of the stomach
Taking into account that NaHCO 3 is quite commonly used, the very few reported cases support that this fatal complication is extremely rare. The ingestion of ½ teaspoon of NaHCO 3 , i.e., 2.5 g, resulted in only small amounts of sudden gas release that were not sufficient to cause spontaneous rupture. 23 To avoid the risk of stomach rupture, patients should take NaHCO 3 between meals not at a high dose and never after a large meal. 23 
Sodium (volume) overload
In short-term and long-term studies (maximum of 5 years), NaHCO 3 supplementation did not elevate blood pressure or require increased dose of anti-hypertensive agents. 15, 17 In a small study of patients with advanced CKD, Husted et al. 24 observed that short-term NaHCO 3 supplementation at a dose of 200 mEq/day caused Na excretion that was higher than the amount excreted with equivalent NaCl supplementation. Furthermore, NaHCO 3 did not increase blood pressure in contrast to NaCl. The dose of NaHCO 3 in these studies was much higher (200 mEq/day vs. 24-36 mEq/day) than that typically used in CKD treatment. A more typical daily dose of NaHCO 3 used to treat metabolic acidosis in CKD (2-3 g) is 0.54-0.81 g (23.22-44.83 mmol) of sodium, i.e., less than the recommended daily dietary sodium for hypertension and CKD (o2 g/day). In addition, whether excessive sodium restriction is actually healthy for CKD patients will be determined in future studies. In CKD patients with and without congestive heart failure, lower and higher sodium levels are both associated with higher mortality. 25 Accordingly, NaHCO 3 , compared with NaCl, might be considered as a comparatively safe sodium source for CKD patients, especially for those whose hypertension is treated with hypotensive agents, such as angiotensin-converting enzyme inhibitors.
F þ V contain largely base-producing proteins and therefore might be considered as a strategy to reduce dietary acid. 17 Thirty days of added F þ V attenuated kidney injury similarly to NaHCO 3 , 15 reduced systolic blood pressure and b.w., 15, 17 and provided antioxidants that are helpful for CKD patients. Although added F þ V was associated with the potential benefit of reduced urinary sodium excretion, it was 
k urine aldosterone excretion k ratio of active to inactive urine cortisol metabolites Susantitaphong et al. 18 meta-analysis Short term (p7days) two studies, n ¼ 17; and long term (X2 months) four studies, n ¼ 295
21-180 mEq/day
In long-term studies, mean net changes in GFR, serum creatinine level, and serum urea nitrogen level occurred, that were beneficial for CKD patients. Increased serum bicarbonate and decreased serum potassium and chloride concentrations were also observed. Systolic and diastolic blood pressure were not affected by long-term NaHCO 3 administration. The meta-analysis revealed that NaHCO 3 therapy produced a net improvement in GFR of 3.2 ml/min per 1.73 m 2 and a 79% reduction in the incidence of dialysis requirement Abbreviations: b.w., body weight; CKD, chronic kidney disease; Cr, creatinine; eGFR, estimated glomerular filtration rate; ESRD, end-stage renal disease; ET-1, endothelin-1.
also associated with increased potassium excretion due to the concomitant higher potassium intake associated with F þ V. The latter could be problematic in CKD patients whose potassium excretory capacity is lower owing to their reduced GFR. 15, 17 Dietary alkalinization with NaHCO 3 avoids concomitant potassium ingestion inherent with F þ V, more effectively reduces the aldosterone levels associated with decreased GFR, 9 and is possibly associated with better compliance than F þ V. Therefore, oral NaHCO 3 appears to be a safer, more accessible, and less expensive dietary alkalization strategy for CKD patients.
INTERACTIONS
By changing the stomach and urinary tract pH, NaHCO 3 can affect the absorption and excretion of various substances. Table 3 shows the most important interactions of NaHCO 3 and different popular drugs (http://toxnet.nlm.nih.gov/cgibin/sis/search/f?./temp/~cjQKuV:1). To avoid interactions in the pharmaceutical phase (i.e., chemical reactions in the stomach), NaHCO 3 should not be simultaneously taken with other medications (a 1-to 2-h interval is recommended). Importantly, NaHCO 3 does not interact with anti-hypertensive drugs.
DOSAGE
The optimal daily dose of NaHCO 3 that provides kidney protection and yet minimizes side effects remains to be determined. The National Kidney Foundation recommends 0.5-1.0 mEq of NaHCO 3 /kg b.w. in patients with HCO 3 o22 mmol/l. The quantity of base required to increase serum HCO 3
À by a given amount can be calculated according to the following formula: (desired HCO 3
. 26 Because metabolic acidosis increases the space of distribution of administered HCO 3 , 27 CKD patients with metabolic acidosis might require slightly more administered HCO 3 than suggested by this formula. In studies in patients with CKD and HCO 3 o22 mmol/l, the usual dose was 1 mEq/kg b.w. such that a 70-kg patient received approximately 5.9 g of NaHCO 3 daily. In the study by de Brito-Ashurst et al., 13 patients started therapy under a dosing regimen of 3Â600 mg, and the average dose of NaHCO 3 was 1.82±0.80 g/day. The serum HCO 3 À level was monitored every 2 months. In CKD patients without acidosis, NaHCO 3 was administered at a dose of 0.5 mEq, i.e., 42 mg/kg b.w. daily (patients weighing 70 kg received approximately 3 g of NaHCO 3 divided in three doses). 14 Susantitaphong et al. 18 recommended 0.5 mEq /kg b.w. daily in their meta-analysis. Rutkowski and Ciechanowski 22 in their review recommended the use of NaHCO 3 when serum HCO 3 is o22 mmol/l or eGFR is o60 ml/min per 1.73 m 2 (usually, the serum HCO 3 À concentration in such case is lower by 2 mmol/l relative to patients with GFR 480 ml//min).
GALENIC FORMS
The tolerance and compliance of patients using NaHCO 3 depends on the galenic form of this substance (Table 4 ) (from reference Krapf et al. 28 ). Tablets and capsules are well tolerated by patients, and the dose can be better controlled. Some manufacturers add flavors to improve the taste of tablets. The official status of NaHCO 3 depends on local regulations. In some countries, NaHCO 3 is registered as a drug, whereas it is registered in other countries as a food supplement. It can also be registered as both a food supplement and a drug.
Regulations regarding medical use of NaHCO 3 are confusing for patients and for medical practitioners. People often do not trust food supplements or products available outside of pharmacies. Nevertheless, there is no chemical difference between baking soda bought in the supermarket and NaHCO 3 powder or tablets bought in pharmacies. Only in the pharmacy, however, can patients be professionally advised regarding interactions, side effects, and warnings. Dosing with powder is less precise than with tablets. In addition, its temperature sensitivity makes storage of NaHCO 3 challenging. Consequently, the better recommendation for CKD patients is NaHCO 3 prescribed and purchased as tablets or capsules from a pharmacy rather than from a supermarket. Other alkali products are also available (e.g., Na citrate, K citrate, Ca citrate, Ca acetate, Ca carbonate), but only NaHCO 3 and Na citrate were the subject of clinical studies concerning CKD progress prevention. NaHCO 3 has some advantages, including its reduced cost, not being associated with increased gastric aluminum absorption, and not providing exogenous calcium with the recent concern that the latter might further increase the already increased cardiovascular risk of CKD. In Table 5 is shown a comparison of different alkali products, which can help individualize the therapy.
CONTRAINDICATIONS
NaHCO 3 is contraindicated in patients with metabolic or respiratory alkalosis and in those with hypocalcemia in whom alkalosis may induce tetany, hypochloremia, and hypokalemia. It should also be used with caution in patients with chronic obstructive pulmonary disease, because alkalization can reduce the sensitivity of the respiratory regulatory center. 
